Landos Biopharma, Inc.
LABPDelisted May 23, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785345
Landos Biopharma, Inc. was delisted on May 23, 2024; its insiders filed their last Form 4 on May 23, 2024; 16 institutions reported holding it in 13F filings for Q1 2024, worth $34.9M in total; no superinvestor held it.
13F holders, Q1 2024
Institutional positions in Landos Biopharma, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
LABP is no longer listed, so this page shows Q1 2024. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 16
- +6 vs. Q4 2023
- Shares held
- 1.62M
- +96.8K (+6.3%) vs. Q4 2023
- Total value
- $34.9M
- +$29.3M (+525.5%) vs. Q4 2023
- New holders
- 7
- 2 more added
- Sold out
- 1
- 0 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LABP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 16 | $34.9M |
| Q4 2023 | 10 | $5.58M |
| Q3 2023 | 11 | $5.93M |
| Q2 2023 | 8 | $6.27M |
| Q1 2023 | 20 | $4.63M |
| Q4 2022 | 23 | $7.87M |
| Q3 2022 | 31 | $14.0M |
| Q2 2022 | 35 | $16.4M |
| Q1 2022 | 45 | $35.3M |
| Q4 2021 | 40 | $119.8M |
| Q3 2021 | 35 | $331.1M |
| Q2 2021 | 33 | $261.4M |
| Q1 2021 | 47 | $218.9M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Landos Biopharma, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 10 | $215 | 0.00% | 00.0% | Unchanged |
| Cornerstone Planning Group LLC | 12 | $267 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 13 | $279 | 0.00% | +13 | New |
| Royal Bank of Canada | 61 | $1.00K | 0.00% | +61 | New |
| JPMorgan Chase & Co | 59 | $1.27K | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 134 | $2.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 896 | $19.2K | 0.00% | +896 | New |
| UBS Group AG | 4,084 | $87.7K | 0.00% | +4,042+9,623.8% | Added |
| Black Maple Capital Management LP | 10,405 | $223.5K | 0.15% | +10,405 | New |
| PenderFund Capital Management Ltd. | 9,300 | $270.8K | 0.07% | +9,300 | New |
| Geode Capital Management, LLC | 12,604 | $271.0K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 14,537 | $313.0K | 0.02% | +14,537 | New |
| Macquarie Group Ltd | 14,718 | $316.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 18,890 | $406.0K | 0.00% | +7,630+67.8% | Added |
| Deltec Asset Management LLC | 50,000 | $1.07M | 0.21% | +50,000 | New |
| Perceptive Advisors LLC | 1,486,991 | $31.9M | 0.56% | 00.0% | Unchanged |
| BlackRock Inc. | 0 | $0 | 0.00% | −42−100.0% | Sold out |